Baseline interleukin-6 is a prognostic factor for patients with metastatic breast cancer treated with eribulin. Bun A, Nagahashi M, Kuroiwa M, Komatsu M, et al. Breast Cancer Res Treat 2023 Sep 21. doi: 10.1007/s10549-023-07086.

Read + Share

Amedeo Smart

Independent Medical Education

Bun A, Nagahashi M, Kuroiwa M, Komatsu M, et al. Baseline interleukin-6 is a prognostic factor for patients with metastatic breast cancer treated with eribulin. Breast Cancer Res Treat 2023 Sep 21. doi: 10.1007/s10549-023-07086.
PMID: 37733188